Skip to content

Author

A. Ashoorzadeh

We have 3 of 56 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a MyD88-dependent manner

Abstract Background Immune checkpoint inhibitor therapy can elicit deep and durable immune responses in patients with cancer, although most do not experience long-term remission. Tumor hypoxia contributes to this treatment failure. We tested whether the clinical-stage hypoxia-activated prodrug tarloxotinib enhances imm...

Zhe Fu, V. Jackson-Patel, K. Farrand et al. · 0 citations
Open access Aug 2026

A cryptic allosteric pocket shapes isoform‐selective inhibition of human malic enzymes

Malic enzymes (ME) regulate central carbon metabolism and cellular redox balance, and the mitochondrial isoform ME2 is frequently upregulated in aggressive cancers to support metabolic flexibility and stress resistance. Isoform‐selective inhibition has remained out of reach because the catalytic machinery is essentiall...

Ben A. Krinkel, Y. Yosaatmadja, M. Slayton et al. · 0 citations
Sep 2026

Rational design of hybrid hydrazide-hydrazone/thiourea derivatives as potential VEGFR-2 targeting anticancer agents: synthesis, biological evaluation, and mechanistic insights into anticancer activity.

Overall, this study identifies MIH-36 as a promising lead compound with a multifaceted anticancer activity profile, associated with reduced proliferation, migration, and survival of breast cancer cells, potentially through modulation of VEGFR-2-associated pathways.

Guzide Satir-Basaran, Ahmed Amleh, Antonio Curcio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.